Adagene/ADAG

$2.55

-2.72%
-
1D1W1MYTD1YMAX

About Adagene

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Ticker

ADAG

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Peter Luo

Employees

174

Headquarters

Suzhou, China

Adagene Metrics

BasicAdvanced
$113M
Market cap
-
P/E ratio
-$0.43
EPS
-
Beta
-
Dividend rate
$113M
$4.38
$1.10
35K
3.606
19.19
31.09
-14.13%
-24.66%
-20.87%
6.266
1.607
1.608
94.9%
76.57%
195.64%

What the Analysts think about Adagene

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 3 analysts.
370.59% upside
High $26.00
Low $5.00
$2.55
Current price
$12.00
Average price target

Adagene Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,850% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$800K
-95.35%
Net income
-$15M
260.98%
Profit margin
-1,850%
7,663.32%

Adagene Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.45%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Actual
-$0.87
-
-
Expected
-$0.93
-$0.42
-$0.42
Surprise
-6.45%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Adagene stock?

Adagene (ADAG) has a market cap of $113M as of May 20, 2024.

What is the P/E ratio for Adagene stock?

The price to earnings (P/E) ratio for Adagene (ADAG) stock is 0 as of May 20, 2024.

Does Adagene stock pay dividends?

No, Adagene (ADAG) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Adagene dividend payment date?

Adagene (ADAG) stock does not pay dividends to its shareholders.

What is the beta indicator for Adagene?

Adagene (ADAG) does not currently have a Beta indicator.

What is the Adagene stock price target?

The target price for Adagene (ADAG) stock is $12, which is 370.59% above the current price of $2.55. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Adagene stock

Buy or sell Adagene stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing